Bladder Cancer Treatment Updates
Publish place: 17th Congress of the Iranian Society for Oncology and Hematology and the Annual Cancer Nursing Conference
Publish Year: 1397
Type: Conference paper
Language: English
View: 362
این Paper فقط به صورت چکیده توسط دبیرخانه ارسال شده است و فایل کامل قابل دریافت نیست. برای یافتن Papers دارای فایل کامل، از بخش [جستجوی مقالات فارسی] اقدام فرمایید.
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- I'm the author of the paper
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
Export:
Document National Code:
ISMOH17_064
Index date: 30 April 2019
Bladder Cancer Treatment Updates abstract
Urothelial carcinoma is the sixth most common malignancy in the United States. Althoughmost are diagnosed with no- muscle-invasive malignancy, many patients will developrecurrent disease within years, with 10% to 20% developing advanced muscle-invasive ormore distant incurable disease. Despite multidisciplinary advances in urothelial carcinoma, clinical outcomes remainsuboptimal for those with advanced disease, with 5-year survival rates typically less than15%. For patients with metastatic disease, first-line platinum-based chemotherapy remainsstandard of care for those who are cisplatin eligible. For patients with recurrent disease after chemotherapy, there has been FDA approval of fivediff erent PD-1/ PD-L1 inhibitors since May 2016, with both atezolizumab andpembrolizumab also approved as first-line therapy for patients ineligible to receive cisplatinchemotherapy. There are number of promising targeted therapies currently undergoing study in advancedurothelial carcinoma, including VEGF receptor antibodies, selective FGFR inhibitors, andantibody-drug conjugates such as enfortumab vedotin, targeting Nectin-4. As multitude of drugs continue to be invetigated, the treatment paradigm continues tochange with ongoing research aimed at how best to incorporate these newer agents withcurrent well-established therapies or in novel combinations with other treatment modalitiesat various stages of disease.
Bladder Cancer Treatment Updates authors
Sina Salari M.D
Assistant Professor of Hematology Oncology School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran